Tanshinone IIA Inhibits Triple-Negative Breast Cancer Cells MDA-MB-231 via G Protein-Coupled Estrogen Receptor-

Yueshuang He1, Ke Yang2, Jiao Liu1

  • 1School of Life Sciences, Beijing University of Chinese Medicine, No. 11 East Road, North 3rd Ring Road, Beijing 100029, China.

Disease Markers
|February 6, 2023
PubMed

Insights

Tanshinone IIA, derived from Chinese medicine, inhibits triple-negative breast cancer (TNBC) cell growth and migration. This effect is mediated through the G protein-coupled estrogen receptor (GPER), suggesting GPER as a potential therapeutic target for TNBC.

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies due to absent classic estrogen receptors.
  • G protein-coupled estrogen receptor (GPER) is expressed in TNBC cells.
  • Tanshinone IIA (Tan IIA) from Salvia miltiorrhiza shows anticancer properties.

Purpose of the Study:

  • To investigate the role of GPER in the anti-TNBC effects of Tan IIA.
  • To elucidate the underlying molecular mechanisms of Tan IIA action in TNBC.

Main Methods:

  • Bioinformatics analysis (database mining, GO pathway analysis)
  • Molecular docking
  • Cell viability assays (CCK8)
  • Cell migration assays (Transwell)
  • Apoptosis assays (flow cytometry)
  • Western blotting for protein expression analysis
  • GPER inhibition studies

Main Results:

  • Tan IIA demonstrated strong binding to GPER.
  • Tan IIA inhibited proliferation, migration, and induced apoptosis in MDA-MB-231 TNBC cells.
  • Tan IIA downregulated GPER, EGFR, ERK, c-Fos, and c-Jun expression.
  • GPER inhibition partially reversed Tan IIA's effects.
  • Tan IIA reduced nuclear translocation of c-Fos, c-Jun, and cell cycle proteins.

Conclusions:

  • Tan IIA exhibits anti-TNBC activity by inhibiting proliferation and migration while inducing apoptosis.
  • The mechanism involves GPER-mediated pathways, including downregulation of key signaling proteins.
  • GPER represents a promising therapeutic target for TNBC treatment.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K